Kansas hearing lays out how 340B grew and why federal reform and transparency are back on the agenda

TOPEKA, Kan. — Lawmakers on a Kansas special committee on Oct. 25 heard competing views on how the federal 340B drug-pricing program has expanded since 1992 and whether Congress should act to require more transparency and protect the program’s original safety‑net purpose.

The hearing brought policy analysts, hospital and clinic leaders, pharmacists, employer representatives and advocates to explain how 340B discounts are generated and distributed and to describe federal bills and pilot programs now under discussion in Washington.

“The 340B program has had a profound impact on the landscape of American health care,” Jackson Hammond, senior policy analyst at Paragon Health Institute, told the committee. “The impacts include increased consolidation, higher drug prices, and increased health insurance premiums.”

Why it matters: 340B requires drug manufacturers to sell outpatient medicines at discounted prices to qualifying safety‑net providers, a mechanism intended to help hospitals and clinics stretch federal resources for uninsured and low‑income patients. Witnesses said the program has become much larger than Congress anticipated, producing both benefits for some providers and concerns about growth, opaque revenue flows and downstream cost effects for…